Home The Word Brain	My Amedeo FAQ Privacy About
	CC Journal Club Our weekly journal club for junior residents and medical students

Lung Cancer

Free Subscription 14.04.2025 2 Ann Thorac Surg 9 BMC Cancer 3 Br J Cancer 1 Cancer Lett 1 Cancer Res 3 Chest 1 Int J Radiat Oncol Biol Phys 1 J Thorac Cardiovasc Surg 7 J Thorac Oncol 15 Lung Cancer 1 Mol Carcinog 1 Nat Med 1 Nat Rev Cancer 1 Oncogene 1 Oncologist 1 PLoS Comput Biol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Thorac Surg

1. VANWINKLE CK, Fu W, Hassett KP, Thompson MP, et al
   The Association between Participation in a Quality Collaborative and Value in Lung Cancer Surgery.
   Ann Thorac Surg. 2025 Apr 5:S0003-4975(25)00295.
   PubMed         Abstract available
   
   
2. RUSCH VW
   An unresolved surgical conundrum: How to manage unsuspected nodal involvement in early-stage lung cancer.
   Ann Thorac Surg. 2025 Apr 2:S0003-4975(25)00282.
   PubMed        
   
   

   
   BMC Cancer

3. CAPDEVILA J, Pubul V, Anido U, Walter T, et al
   A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
   BMC Cancer. 2025;25:613.
   PubMed         Abstract available
   
   
4. XU S, Yin SY, Bie ZX, Li YM, et al
   Personalized drug screening of patient-derived tumor-like cell clusters based on specimens obtained from percutaneous transthoracic needle biopsy in patients with lung malignancy: a real-world study.
   BMC Cancer. 2025;25:649.
   PubMed         Abstract available
   
   
5. LI J, Xu HL, Li WX, Ma XY, et al
   Prognostic factors of survival in patients with lung cancer after low-dose computed tomography screening: a multivariate analysis of a lung cancer screening cohort in China.
   BMC Cancer. 2025;25:646.
   PubMed         Abstract available
   
   
6. TAJE R, Gallina FT, Caterino M, Forcella D, et al
   Molecular characterization of early-stage lung adenocarcinoma presenting as subsolid nodules in a real-life European cohort.
   BMC Cancer. 2025;25:647.
   PubMed         Abstract available
   
   
7. MEI K, Feng Z, Liu H, Wang M, et al
   Preoperative prediction of pulmonary ground-glass nodule infiltration status by CT-based radiomics combined with neural networks.
   BMC Cancer. 2025;25:659.
   PubMed         Abstract available
   
   
8. LEI Y, Cao C, Tang R, Liu Y, et al
   Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opi
   BMC Cancer. 2025;25:664.
   PubMed         Abstract available
   
   
9. LI Y, Zhou J, Liu L, Zhu C, et al
   Association of SNPs in nAChRs genes, areca nut chewing and smoking, and their interaction with lung cancer in Hainan, China: a case control study.
   BMC Cancer. 2025;25:626.
   PubMed         Abstract available
   
   
10. YIN X, Lin X, Zhang G, Yin Y, et al
    Intensity-modulated proton therapy for hippocampal-sparing prophylactic cranial irradiation: a planning comparison with photon therapy.
    BMC Cancer. 2025;25:639.
    PubMed         Abstract available
    
    
11. SANG H, Liu J, Chen X, Zeng Y, et al
    METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling.
    BMC Cancer. 2025;25:641.
    PubMed         Abstract available
    
    

    
    Br J Cancer

12. WANG M, Kim RY, Kohonen-Corish MRJ, Chen H, et al
    Particulate matter air pollution as a cause of lung cancer: epidemiological and experimental evidence.
    Br J Cancer. 2025 Apr 4. doi: 10.1038/s41416-025-02999.
    PubMed         Abstract available
    
    
13. COLANGELO T, Mazzarelli F, Cuttano R, Dama E, et al
    Unveiling the origin and functions of diagnostic circulating microRNAs in lung cancer.
    Br J Cancer. 2025 Apr 4. doi: 10.1038/s41416-025-02982.
    PubMed         Abstract available
    
    
14. HUGHES DJ, Chand G, Johnson J, Tegala R, et al
    PD-L1 imaging with [(99m)Tc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancer.
    Br J Cancer. 2025 Apr 5. doi: 10.1038/s41416-025-02991.
    PubMed         Abstract available
    
    

    
    Cancer Lett

15. XIAO X, Huang L, Li M, Zhang Q, et al
    Intersection between lung cancer and neuroscience: opportunities and challenges.
    Cancer Lett. 2025 Apr 5:217701. doi: 10.1016/j.canlet.2025.217701.
    PubMed         Abstract available
    
    

    
    Cancer Res

16. LIU C, Du H, Yu G, Qi J, et al
    Chronic Stress Stimulates Protumor Macrophage Polarization to Propel Lung Cancer Progression.
    Cancer Res. 2025 Apr 9. doi: 10.1158/0008-5472.CAN-24-3481.
    PubMed         Abstract available
    
    

    
    Chest

17. KIM BG, Nam H, Hwang I, Choi YL, et al
    The Growth of Screening-Detected Pure Ground-Glass Nodules Following 10 Years of Stability.
    Chest. 2025;167:1232-1242.
    PubMed         Abstract available
    
    
18. FRANQUET T, Raoof S, Lee KS, Han J, et al
    Lung Nodules and Masses in Patients Who Are Not HIV Immunocompromised: A Clinical Imaging Algorithmic Approach.
    Chest. 2025;167:1142-1160.
    PubMed         Abstract available
    
    
19. TRAN K, Ho ATN, Locher K, Sagar AS, et al
    A 57-Year-Old Man With Persistent Miliary Pattern Pulmonary Nodules and New Lung Masses on Chest CT Scan.
    Chest. 2025;167:e113-e117.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

20. SIMONE CB 2ND, Amini A, Chetty IJ, Choi JI, et al
    American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer Executive Summary.
    Int J Radiat Oncol Biol Phys. 2025 Apr 2:S0360-3016(25)00259.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

21. ANTONOFF MB, Gay CM
    Timing of local consolidative pulmonary resection for oncogene-driven stage IV lung cancer.
    J Thorac Cardiovasc Surg. 2025 Apr 3:S0022-5223(25)00281.
    PubMed        
    
    

    
    J Thorac Oncol

22. LEUNISSEN DJG, Moonen L, von der Thusen JH, den Bakker MA, et al
    Identification of Defined Molecular Subgroups on the Basis of Immunohistochemical Analyses and Potential Therapeutic Vulnerabilities of Pulmonary Carcinoids.
    J Thorac Oncol. 2025;20:451-464.
    PubMed         Abstract available
    
    
23. BOERI M, Zanghi A, Pastorino U
    New Horizons in Lung Cancer Screening: Eligibility Criteria, Risk Models, and Emerging Challenges.
    J Thorac Oncol. 2025;20:422-424.
    PubMed        
    
    
24. KIM YW, Lee CT
    Advancing the Implementation of Risk Model-Based Lung Cancer Screening.
    J Thorac Oncol. 2025;20:419-421.
    PubMed        
    
    
25. PARIKH K, Hashmi A, Chauhan PS, Chaudhuri AA, et al
    Plasma-First Testing in Advanced Lung Cancer: Evidence and Implications.
    J Thorac Oncol. 2025;20:411-414.
    PubMed        
    
    
26. XIA Y, Wang K, Zhao J, Arter Z, et al
    Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.
    J Thorac Oncol. 2025;20:465-474.
    PubMed         Abstract available
    
    
27. NAKAGAWA K, Garon EB, Seto T, Nishio M, et al
    RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
    J Thorac Oncol. 2025;20:487-499.
    PubMed         Abstract available
    
    
28. BLECHTER B, Hsiung CA, Wang X, Zhang H, et al
    Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report.
    J Thorac Oncol. 2025;20:521-530.
    PubMed         Abstract available
    
    

    
    Lung Cancer

29. ISAKA M, Notsu A, Kojima H, Konno H, et al
    Comparative validation of nodal classifications in resected non-small cell lung cancer based on the anatomical location and number of involved stations.
    Lung Cancer. 2025;203:108511.
    PubMed         Abstract available
    
    
30. SOO RA, Vervita K, Fruh M, Cho BC, et al
    A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.
    Lung Cancer. 2025;202:108454.
    PubMed         Abstract available
    
    
31. KAWAKITA N, Takehara E, Takeuchi T, Fujimoto K, et al
    Advantages of a larger working channel diameter of ultrathin bronchoscope in cone-beam computed tomography-guided transbronchial biopsy for diagnosing peripheral lung lesions.
    Lung Cancer. 2025;202:108483.
    PubMed         Abstract available
    
    
32. GARASSINO MC, He Y, Ahn MJ, Orlov SV, et al
    Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study.
    Lung Cancer. 2025;202:108417.
    PubMed         Abstract available
    
    
33. LAVEN IEWG, Franssen AJPM, Gronenschild MHM, Heineman DJ, et al
    National clinical practice patterns of uniportal video-assisted thoracoscopic anatomical lung resections: nationwide population-based data from a clinical audit registry.
    Lung Cancer. 2025;202:108481.
    PubMed         Abstract available
    
    
34. TORASAWA M, Yoshida T, Shiraishi K, Yagishita S, et al
    Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma.
    Lung Cancer. 2025;202:108494.
    PubMed         Abstract available
    
    
35. AHUJA G, Iyer A, Harwood R, Balata H, et al
    Pathological & radiological variables in the diagnosis of bronchopulmonary carcinoids (BPCs) with a focus on Antigen Kiel 67 (Ki-67) proliferation index.
    Lung Cancer. 2025;202:108493.
    PubMed         Abstract available
    
    
36. MESSEKHER M, Fuchs F, Badr M, Pujol JL, et al
    Gefitinib for EGFR mutated lung adenocarcinoma during pregnancy: A case report with 5-Year Follow-Up.
    Lung Cancer. 2025;202:108456.
    PubMed         Abstract available
    
    
37. FAN M, Yan W, Zhuo M, Yu R, et al
    Feasibility and safety of perioperative entrectinib in a patient with ROS1-positive locally advanced NSCLC: A case report.
    Lung Cancer. 2025;202:108501.
    PubMed         Abstract available
    
    
38. TAKAMOCHI K, Suzuki K, Okada M, Niho S, et al
    CRES(3)T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumors.
    Lung Cancer. 2025;202:108506.
    PubMed         Abstract available
    
    
39. AN Z, Ning Y, Mei J, Yang C, et al
    Evaluating the prognostic impact of EGFR mutation on adjuvant chemotherapy efficacy in grade 3 stage IB lung adenocarcinoma.
    Lung Cancer. 2025;202:108507.
    PubMed         Abstract available
    
    
40. LINDBERG S, Grozman V, Karlsson K, Onjukka E, et al
    Stereotactic body radiation therapy (SBRT) of centrally located medically inoperable early-stage non-small cell lung cancer (T1-T3N0M0) - A subgroup analysis of the expanded HILUS study.
    Lung Cancer. 2025;203:108527.
    PubMed         Abstract available
    
    
41. CHEN H, Cai W, Han Y, Zhao Y, et al
    Associations between carbohydrate quality and the survival of, and life expectancy with lung cancer patient: A prospective cohort study.
    Lung Cancer. 2025;203:108508.
    PubMed         Abstract available
    
    
42. AVANCINI A, Giaj-Levra N, Minuti G, Pasqualini G, et al
    Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study.
    Lung Cancer. 2025;203:108531.
    PubMed         Abstract available
    
    
43. ADDO S, Lycan T, Soto-Pantoja DR, Tsai YT, et al
    Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status.
    Lung Cancer. 2025;203:108513.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

44. LI X, Wu Y, Xie B, Xu M, et al
    SPP1 Promotes NSCLC Brain Metastasis Via Sequestration of Ubiquitin Ligase RNF114 to Facilitate P85alpha Ubiquitination.
    Mol Carcinog. 2025;64:829-841.
    PubMed         Abstract available
    
    

    
    Nat Med

45. ZHAO S, Cheng Y, Wang Q, Li X, et al
    Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.
    Nat Med. 2025 Apr 10. doi: 10.1038/s41591-025-03638.
    PubMed         Abstract available
    
    

    
    Nat Rev Cancer

46. SIMPSON KL, Rothwell DG, Blackhall F, Dive C, et al
    Challenges of small cell lung cancer heterogeneity and phenotypic plasticity.
    Nat Rev Cancer. 2025 Apr 10. doi: 10.1038/s41568-025-00803.
    PubMed         Abstract available
    
    

    
    Oncogene

47. XU X, Wang S, Zhou H, Tan Q, et al
    Transcriptome-wide association study of alternative polyadenylation identifies susceptibility genes in non-small cell lung cancer.
    Oncogene. 2025 Apr 9. doi: 10.1038/s41388-025-03338.
    PubMed         Abstract available
    
    

    
    Oncologist

48. BAUTISTA-GONZALEZ E, Munoz Rocha TV, Soto-Perez-de-Celis E, Vindrola-Padros C, et al
    Treatment delays in patients with lung cancer: a retrospective study conducted at the National Cancer Institute of Mexico between 2004 and 2021.
    Oncologist. 2025;30:oyae358.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

49. JIN Z, Zhou X, Fang Z
    DelaySSA: stochastic simulation of biochemical systems and gene regulatory networks with or without time delays.
    PLoS Comput Biol. 2025;21:e1012919.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.